[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"treatment-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:treatment-complication":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100425752","the-role-of-wearable-devices-in-predicting-and-detecting-complications-and-adverse-events-100425752",false,"NCT04824066","The Role of Wearable Devices in Predicting and Detecting Complications and Adverse Events","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Individuals scheduled to undergo one of the following surgical or non-surgical treatments: cardiothoracic surgery, orthopedic surgery, vascular surgery, colorectal surgery, pancreatic surgery, other major abdominal surgeries, treatment for chronic disease, or systemic therapy (i.e., chemotherapy, immunotherapy, or targeted therapy), radiotherapy, or ablation.\n3. Amenable to using one of the wearable devices of interest (Fitbit, iWatch, Biostrap).\n4. Individuals willing to provide informed consent and who have capacity for all study procedures\n\nExclusion Criteria:\n\n1. Individuals with mental incapacity and\u002For cognitive impairment that would preclude adequate understanding of, or cooperation with the study protocol.\n2. Any pregnant participant.","ALL","18 Years",{"count":18,"type":19},2400,"ESTIMATED","OBSERVATIONAL","The overarching goal of this research is to use machine learning analysis of high-resolution data-collected by wearable technology-to predict complications and poor recovery in patients undergoing treatment for benign or malignant conditions.",[23,24],"Recovery","Treatment Complication","RECRUITING","2026-05-24",{"date":28,"type":29},"2026-05-28","ACTUAL",{"date":31,"type":29},"2021-07-10",{"date":33,"type":19},"2029-06-30",{"name":35,"class":36},"Massachusetts General Hospital","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":37},"100527779","functional-outcome-after-orif-or-arthroplasty-for-femoral-neck-fracture-100527779","NCT06152198","Functional Outcome After ORIF or Arthroplasty for Femoral Neck Fracture","Internal Fixation Versus Hip Replacement in Older Adults with an Garden I\u002FII Femoral Neck Fracture: Physical Function and Pain in Elderly Patients - a Substudy of the Hipsther Trial","HipFunct","Inclusion Criteria:\n\n* Undisplaced (Garden I-II) femoral neck fracture (within 72h)\n* Treated at participating unit\n* Informed consent\n* Amenable for both treatment options\n* Included in the Hipsther trial\n\nExclusion Criteria:\n\n* No informed consent\n* Pathological or stress fracture\n* Peri-implant fracture\n* Previous inclusion of a contralateral Garden 1 or 2 femoral neck fracture","75 Years",{"count":48,"type":19},340,"INTERVENTIONAL",[51],"NA","Aim To investigate the effect of internal fixation versus hip arthroplasty on physical function and pain in elderly patients.\n\nMethods This is a substudy of an on-going nationwide multicenter registry-based RCT named HipSTHeR- (Hip Screws or Total Hip replacement or undisplaced femoral neck fracture in elderly patients) \\[21\\]. The aim is to recruit 340 patients with undisplaced or minimally displaced femoral neck fracture, Garden 1 or 2, are randomized to surgery either with internal screw fixation or hip arthroplasty.\n\nThis substudy aims to investigate the potential differences between internal fixation versus hip arthroplasty regarding physical function and pain 4- and 12- months after surgery. Those included in the main study will be contacted by letter a few weeks after the surgery to be invited to participate in a further study. The assessor will then contact the person by telephone to answer further questions and to obtain informed consent. The follow-ups will be conducted over telephone and mail at 4 and 12 months. During the follow-up the participants will answer questions about their functional level.\n\nInformation on randomisation and fracture data will be acquired from the Swedish Fracture Register and treatment data from the Swedish Hip Arthroplasty Register.\n\nPrimary outcome The New Mobility Score will be used as the primary outcome with follow-up at 4- and 12 months.\n\nSecondary outcome WOMAC will be used as an additional hip specific patient reported outcome.\n\nActivities of daily living will be assessed with Katz ADL index to evaluate the patients' performance and the need of assistance in ADL.\n\nPatients' cognitive status will be assessed ALFI-MMSE, adapted from Adult Lifestyles and Function Interview (ALFI-MMSE).\n\nThe Geriatric Depression Scale (GDS-15), which are developed to identify depressive symptoms.\n\nThe Philadelphia Geriatric Center Morale Scale (PGCMS) and have been used in several studies including frail people living in residential care facilities and can be used among patients with cognitive impairment.",[54,55,56,24,57,58],"Hip Fractures","Femoral Neck Fractures","Undisplaced Fracture","Internal Fixation; Complications","Arthroplasty Complications",[60,61,62,63,64],"hip fracture","femoral neck fracture","treatment","hip arthroplasty","internal fixation","2024-11-28",{"date":67,"type":29},"2024-12-03",{"date":69,"type":29},"2021-06-20",{"date":71,"type":19},"2027-09-01",{"name":73,"class":36},"Uppsala University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":49,"phases":85,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":37},"100544790","improving-quality-of-life-in-older-patients-with-frailty-and-hematological-cancer-through-geriatric-assessment-100544790","NCT06373471","Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment","Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment and Treatment; A Randomized Controlled Trial. IMPROVE","IMPROVE","Inclusion Criteria:\n\n* Age ≥70 years\n* New diagnosis or progression\u002Frelapse of acute leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, chronic myelomonocytic leukemia or myelofibrosis\n* Scheduled systemic cancer treatment or initiated systemic cancer treatment within 6 weeks\n* Geriatric 8 frailty score of ≤14 at screening\n* Life expectancy \\> 6 months\n* Not hospitalized at the time of inclusion\n\nExclusion Criteria:\n\n* Current systemic treatment for other coexisting cancer. Patients receiving anti-hormone treatment for breast cancer or prostate cancer are not excluded, if no evidence of disease progression (radiological\u002Fbiochemical) in past 3 months or if treatment is adjuvant.\n* Having consulted a geriatric outpatient clinic past 6 months\n* Patients in need of specialized neuro-rehabilitation\n* Unable to understand Danish\n* Unable to give written informed consent","70 Years",{"count":84,"type":19},152,[51],"The Improve study is a randomized controlled trial investigating the efficacy of adding comprehensive geriatric assessment and treatment to standard of care compared with standard of care in older, frail patients with hematological cancer. The investigators aim to recruit 152 study participants who will be randomized 1:1 to intervention- or control group. Study participants in the intervention group will receive the intervention comprehensive geriatric assessment and treatment integrated in the cancer treatment. Study participants in the control group will receive cancer treatment and evaluation of comorbidity and frailty as is usual standard at Department of Hematology. Primary endpoint is elderly functional Index at 12 weeks.",[88,89,24,90,91],"Hematologic Malignancy","Treatment Adherence","Frailty","Quality of Life",[93],"Comprehensive Geriatric Assessment","2024-04-17",{"date":96,"type":29},"2024-04-18",{"date":98,"type":29},"2024-04-02",{"date":100,"type":19},"2026-09-30",{"name":102,"class":36},"Odense University Hospital"]